Tuesday, June 23, 2026

Summer Heatwave Skin Protection

Summer Heatwave Skin Protection Infographic

Premanstrual Tension

Monday, June 22, 2026

Yoga is Not a Simple Exercise: How Yoga Differs from "Exercise" — A Clinician's Lens

Sunday, June 21, 2026

Understanding Intrahepatic Cholestasis of Pregnancy (ICP)

Understanding Intrahepatic Cholestasis of Pregnancy (ICP) - A Comprehensive Guide

✍️ Medical Education

Understanding Intrahepatic Cholestasis of Pregnancy (ICP)

A comprehensive guide to clinical features, diagnosis, and evidence-based management

By Dr. Sujnanendra Mishra, MD (Ob & Gyn)

Swaraj Hospital & Research Institute, Bolangir, Odisha

What is Intrahepatic Cholestasis of Pregnancy?

Intrahepatic Cholestasis of Pregnancy (ICP) is the most common liver disease specific to pregnancy. It is characterized by impaired bile acid excretion from the liver, leading to bile acid accumulation and elevated bile acid levels in maternal blood.

ICP is an inflammatory disease of multifactorial etiology that typically presents with new-onset pruritus (intense itching) in the late second or third trimester, often involving the palms and soles, accompanied by elevated serum bile acids.

Key Clinical Feature

The hallmark of ICP is pruritus without a visible rash. This distinguishes it from other dermatological conditions and is a critical clinical clue that should prompt immediate bile acid testing.

0.3-0.5%

Prevalence in Western populations

45-70%

Recurrence in subsequent pregnancies

Epidemiology & Global Prevalence

The prevalence of ICP varies significantly across different populations and geographic regions:

Western Europe: 0.3-0.7% of pregnancies
Hispanic populations: Up to 5.6% (significantly higher)
Asian populations: Higher prevalence, especially from India and Pakistan
Indigenous populations: Some regions report rates up to 22% (e.g., Araucanian Indians in Chile)
Caucasian populations: 0.32% (lower baseline risk)

                    Risk Factors for ICP Development
                    Prior history of ICP (strongest risk factor)
Multiple gestation (twin or higher-order pregnancy)
Hepatobiliary disease history (especially Hepatitis C)
Genetic predisposition and mutations (ABCB4, ABCB11, ATP8B1)
Assisted reproductive technology (ART) stimulation with high estrogen (RR 3.8)
Advanced maternal age
Progesterone supplementation in some cases

                

Clinical Symptoms & Presentation

Patients with ICP typically present with characteristic symptoms that develop acutely:

Primary Symptoms

Intense Pruritus: Sudden-onset severe itching, often worse at night and disturbing sleep
Palmar/Plantar Involvement: Characteristic itching of palms and soles; may affect other areas
Absence of Rash: Pruritus occurs without visible skin manifestation (key distinguishing feature)
Psychological Impact: Significant distress from itching intensity and sleep disruption
Excoriations: Severe scratching may result in skin damage

⚠️ Important Clinical Note

The severity of pruritus does NOT correlate with maternal bile acid levels or fetal risk. Some patients with minimal symptoms have dangerous bile acid levels, while others with severe pruritus have lower levels. This makes routine monitoring essential regardless of symptom severity.

Timing of Presentation

ICP typically manifests in the late second trimester to early third trimester, aligning with peak estrogen and progesterone levels. Early diagnosis (before 18 weeks) is rare and suggests possible underlying hepatic disease requiring hepatology consultation.

How ICP Develops: The Molecular Mechanism

The pathophysiology of ICP is multifactorial, involving genetic, hormonal, and inflammatory mechanisms:

Step 1: Hormonal Trigger

Elevated estrogen and progesterone in late pregnancy inhibit bile acid flow and hepatic excretion pathways

Step 2: Transporter Dysfunction

Impaired hepatocellular transporters (ABC transporters like ABCB4, ABCB11) reduce bile acid elimination

Step 3: Bile Acid Accumulation

Bile acids accumulate intracellularly and are released into maternal blood; stasis triggers inflammation

Step 4: Inflammatory Response

Proinflammatory cytokines are released; accumulation in tissues triggers symptoms and fetal effects

Key Molecular Mechanisms

Taurine-Conjugate Accumulation: Toxic bile acid forms accumulate in fetal cardiac muscle, increasing arrhythmia risk
Oxytocin Receptor Activation: Bile acids increase oxytocin receptors in uterine muscle, elevating preterm labor risk
Placental Dysfunction: Bile acid accumulation in placental tissue may cause vasospasm and reduced fetal perfusion
Genetic Mutations: Alterations in genes encoding bile acid transporters increase ICP susceptibility

Diagnosis & Laboratory Investigation

Diagnosis of ICP requires clinical suspicion followed by laboratory confirmation:

Diagnostic Criteria

                    Clinical + Laboratory Confirmation
                    Clinical: New-onset pruritus without rash in pregnancy
Laboratory: Serum total bile acids (TBA) > 10 µmol/L (fasting) OR > 14 µmol/L (postprandial)

                

Risk Stratification by Bile Acid Levels

< 40

Low Risk (expectant management)

40-100

Moderate Risk (early delivery consideration)

> 100

High Risk (significant fetal danger)

Laboratory Tests

Serum Total Bile Acids (TBA): Primary diagnostic test; no fasting required
Liver Function Tests (LFTs): ALT, AST may be mildly to moderately elevated; ALT often more specific
Bilirubin Levels: Usually normal or mildly elevated; jaundice is uncommon
Differential Diagnosis: Rule out viral hepatitis, gallstones, preeclampsia, HELLP syndrome

Critical Clinical Pearl

Pruritus may precede elevated bile acids by 1-2 weeks. If initial TBA is normal but pruritus persists, repeat testing in 7-14 days. Do not falsely reassure patients based on a single normal bile acid level with ongoing symptoms.

Management & Treatment Strategy

ICP management requires a multidisciplinary approach combining pharmacological therapy, antenatal surveillance, and individualized delivery planning.

First-Line Pharmacological Treatment: Ursodeoxycholic Acid (UDCA)

                    UDCA Dosing & Administration
                    Initial Dose: 10-15 mg/kg/day (typically 300 mg daily)
Maximum Dose: 20 mg/kg/day (typically 300-900 mg divided into 2-3 doses)
Onset of Action: 1-2 weeks for symptom relief
Mechanism: Reduces bile acid reabsorption in the bowel and intrahepatic accumulation
Safety: Well-tolerated; adverse effects minimal (nausea, mild dizziness)

                

Important Treatment Limitation

UDCA improves maternal pruritus but does NOT prevent fetal complications. No evidence supports UDCA reducing stillbirth risk, preterm birth, or other adverse perinatal outcomes. Treatment should focus on symptom relief while obstetric management addresses fetal safety.

Obstetric Management

Antenatal Surveillance

Initiate at time of diagnosis (if gestational age permits intervention for abnormal testing)
Once or twice-weekly non-stress tests (NST)
Measurement of deepest vertical pocket of amniotic fluid
Serial growth ultrasounds at clinician discretion (FGR uncommon with ICP)

Delivery Timing

TBA < 40 µmol/L

Expectant management; plan delivery at term (≥37 weeks)

TBA 40-100 µmol/L

Consider delivery at 36-37 weeks; individualize based on clinical factors

TBA > 100 µmol/L

Strong recommendation for delivery by 36 weeks or earlier; highest fetal risk

Multidisciplinary Team Approach

Optimal ICP management requires coordinated care:

Obstetrics: General obstetric care and antenatal surveillance
Maternal-Fetal Medicine (MFM): Refer if TBA > 40 µmol/L or early diagnosis
Hepatology: Refer if TBA > 100 µmol/L or diagnosis before third trimester
Neonatology: Preparation for potential preterm delivery complications
Pharmacy & Nursing: Patient education and medication management

Maternal & Fetal Complications

While maternal prognosis is generally favorable, ICP carries significant fetal risk that demands careful management.

Maternal Complications

Severe Pruritus: Intense itching causing psychological stress, sleep disturbance, and potential skin damage from scratching
Preeclampsia (3-4x increased risk): Incidence rises from 2.4% to 7.8%; earlier ICP onset correlates with earlier preeclampsia (2-4 weeks)
Coagulopathy Risk: Potential vitamin K malabsorption and prolonged prothrombin time from bile acid stasis
Cardiac Arrhythmias: Direct arrhythmogenic effect of bile acids on cardiomyocytes (no significant clinical consequences)
Gestational Diabetes: Increased incidence from 8.5% to 13.6%; requires glucose monitoring

Fetal & Neonatal Complications

🚨 Most Serious: Sudden Stillbirth

The most concerning fetal complication is sudden intrauterine fetal death. The mechanism appears related to bile acid accumulation in fetal cardiac muscle causing arrhythmias and sudden cardiac arrest. Critically, NO PREDICTIVE MONITORING exists for stillbirth—it can occur suddenly in otherwise healthy pregnancies.

Preterm Birth: Increased incidence due to bile acid-mediated oxytocin receptor activation in uterine muscle
Meconium-Stained Amniotic Fluid: Fetal colonic stimulation from bile acid exposure
Respiratory Distress Syndrome: Risk if preterm delivery occurs
Neonatal Intensive Care Admission: Increased need for NICU monitoring and support
Birth Asphyxia: Risk from placental dysfunction or acute fetal distress

Long-Term Effects

Children born to mothers with ICP have increased risk of:

Elevated body mass index (BMI) by age 16
Dyslipidemia and metabolic abnormalities
Potentially increased cardiovascular risk profile

Risk Correlation: Bile Acid Levels Matter

Fetal risk directly correlates with bile acid concentration. The highest correlation for stillbirth occurs with TBA ≥ 100 µmol/L. This is why bile acid measurement and risk stratification are critical for management decisions.

Key Takeaways & Clinical Practice Points

Six Essential Principles

Early Recognition is Critical: New-onset pruritus without rash in 2nd-3rd trimester is ICP until proven otherwise. Prompt serum bile acid testing prevents diagnostic delays.
Risk Stratification Guides Management: Bile acid levels (not symptom severity) determine fetal risk and delivery timing. TBA > 40 = refer to MFM; TBA > 100 = high risk requiring hepatology input.
UDCA Treats Symptoms, Not Prevention: First-line therapy improves maternal pruritus within 1-2 weeks but provides no fetal protection. Symptom relief should not replace obstetric vigilance.
Fetal Surveillance is Essential: Antenatal monitoring (NSTs, amniotic fluid assessment) from diagnosis onwards. Stillbirth risk is unpredictable despite monitoring—individualized delivery timing is crucial.
High Recurrence in Future Pregnancies: 45-70% of women with ICP will experience recurrence. Early recognition and aggressive management in subsequent pregnancies is vital.
Excellent Maternal Prognosis: Pruritus and liver biochemistry resolve rapidly post-delivery (usually within days to weeks). However, women with ICP have increased long-term risk of hepatobiliary disease requiring follow-up.

Patient Education Essentials

Counsel patients about:

Expected pruritus resolution within days after delivery
High recurrence rate in subsequent pregnancies
Importance of medication compliance and regular monitoring
Attendance at all scheduled antenatal visits and testing
Need for postpartum follow-up if liver abnormalities persist beyond 4-6 weeks

When to Refer to Specialists

Maternal-Fetal Medicine (MFM): Any patient with TBA > 40 µmol/L or diagnosis in first/early second trimester
Hepatology: TBA > 100 µmol/L, ICP diagnosis before third trimester, or underlying hepatic disease history
Neonatology: Anticipated preterm delivery or high-risk cases

Saturday, June 20, 2026

Chicken pox in pregnancy Management protocol

Chickenpox (Varicella) in Pregnancy

Maternal Medicine · Clinical Reference

Chickenpox (Varicella)
during Pregnancy

A protocol for prevention, post-exposure prophylaxis, and active infection — for mother and baby.

BASED ON RCOG & ACOG GUIDELINES

Initial Assessment & Prevention

Determine Immunity

At the first antenatal visit, take a detailed history of prior chickenpox or shingles infection, or varicella vaccination.

If Non-Immune

Advise avoidance of contact with anyone with chickenpox or shingles.
Offer vaccination postnatally — not during pregnancy.
Delay conception 1 month after vaccination.

Management Following Exposure

Step 1

Determine "Significant Exposure"

Contact type: face-to-face, or same small room for 15+ minutes, with someone who has chickenpox, disseminated shingles, or exposed shingles lesions.
Infectious window: 24 hours before rash appears → 5 days after.

Step 2

Determine Susceptibility

Urgent VZV IgG blood test for a susceptible woman with significant exposure.

A reliable history of chickenpox, or two vaccine doses, is itself sufficient evidence of immunity in an immunocompetent woman — no further testing needed.

Step 3

Post-Exposure Prophylaxis (PEP)

Offered if VZV IgG negative (non-immune).

First-line

Oral Antiviral Therapy

Aciclovir or valaciclovir — now the recommended first choice. Given Day 7 to Day 14 after exposure.

Second-line

VZIG

Considered if antivirals are contraindicated (e.g. renal impairment) or not tolerated. A blood product giving passive immunity; effective up to 10 days after contact.

Management of Active Chickenpox

Immediate Action

Contact the healthcare provider immediately, and isolate from other pregnant women.

Risk Profile

10–20%

Pregnant women who develop pneumonia

0.4–2.0%

Risk of fetal varicella syndrome

1st / early 2nd

Trimester = highest fetal risk window

Maternal risks also include hepatitis and encephalitis. Fetal risk depends on gestational age at infection.

Treatment

Route	When indicated
Oral aciclovir	Presenting within 24 hours of rash onset, ≥20 weeks gestation. Use before 20 weeks should also be considered.
IV aciclovir	All pregnant women with severe chickenpox or signs of complications (e.g. respiratory symptoms).

High-Risk Window: Late Pregnancy

Maternal infection from 5 days before to 2 days after delivery carries a high risk of neonatal death. Requires specialist management in a unit with neonatology expertise.

Tuesday, June 16, 2026

EARLY INTERVENTIONS SAVE LIVES

A 32-year-old G2P1 underwent an intrapartum cesarean for arrest of descent after a prolonged labor. She had several PPH risk factors on admission (prolonged oxytocin exposure, chorioamnionitis concern, and uterine overdistension). Because the unit used quantified blood loss (QBL) and maternal early-warning triggers, she was flagged as “high vigilance” pre-incision: second IV placed, uterotonics prepared, blood bank alerted.

In recovery, the team did not rely on “looks like moderate bleeding.” QBL crossed the major hemorrhage trigger within minutes, while her vitals showed early compensated shock (tachycardia with narrowing pulse pressure). A structured PPH call went out immediately with explicit role allocation: one clinician on uterine tone/uterotonics, one on identifying trauma/retained tissue, anesthesia running resuscitation and labs, and a runner coordinating products.

First-line management was rapid and protocolized: bimanual uterine massage, high-dose oxytocin infusion, additional uterotonics, and tranexamic acid while causes were assessed. Despite transient improvement, bleeding persisted and the uterus remained atonic. A bedside ultrasound showed no clear retained products, and repair of a small vaginal laceration did not change bleeding. Within a short, pre-agreed time window—before profound hypoperfusion—the consultant made the call to return to theatre for definitive surgical hemostasis.

The turning point: early laparotomy before irreversible physiology

On re-laparotomy, the uterus was markedly atonic with diffuse bleeding. The team moved quickly through a step wise escalation:

Emergency C-section PPH Case

Uterine compression suture (B-Lynch): A B-Lynch suture was placed to provide immediate mechanical compression of the atonic uterus, aiming to preserve fertility and avoid hysterectomy. (B-Lynch is widely used as a uterus-sparing option and has been described with high success in refractory atony when applied promptly.)
Bilateral uterine artery ligation: Because oozing continued, bilateral uterine artery ligation was performed as a rapid devascularization step. This approach is commonly incorporated into stepwise surgical management of severe PPH and can reduce ongoing blood loss while other measures take effect.⁽²⁾
Bilateral internal iliac (hypogastric) artery ligation: Persistent diffuse bleeding and evolving coagulopathy prompted escalation to bilateral internal iliac artery ligation. This reduced pelvic arterial pulse pressure and bought crucial time for correction of coagulopathy and restoration of circulating volume. The combination of B-Lynch plus internal iliac ligation has been reported as an effective uterus-preserving strategy even in massive PPH complicated by DIC.

In parallel, anesthesia ran a massive hemorrhage resuscitation: active warming, calcium replacement, and goal-directed blood product support (RBC, plasma, platelets, cryoprecipitate/fibrinogen as indicated). Importantly, because the decision for laparotomy happened early, she reached definitive surgical hemostasis before cardiovascular collapse. She stabilized, avoided hysterectomy, and was discharged after an uncomplicated recovery. A debrief emphasized that the uterus was saved not by a single technique, but by timely recognition + decisive escalation.

Why this is a “success story” about early detection

QBL + early-warning triggers converted “post-op bleeding” into a time-critical diagnosis while she was still in compensated shock.
A time-bound escalation plan prevented prolonged “medical-only” management as coagulopathy developed.
Early definitive surgery (B-Lynch → uterine artery ligation → internal iliac ligation) exemplified structured, uterus-sparing escalation that can prevent maternal death from refractory PPH.

Friday, June 5, 2026

The 2026 Acute Pulmonary Embolism (PE) Guidelines

Massive” and “Submassive” Replaced by Clinical Categories: The first-ever AHA/ACC clinical practice guideline on acute pulmonary embolism drops a new A-to-E severity classification.

Key Shift:

The guideline abandons “Massive” and “Sub-massive” labels.
Instead, it uses clinical severity categories (A–E) to better stratify risk and guide therapy.
This improves clarity for front-line clinicians and aligns PE care with modern risk-based management.